Assuring Vaccine Supply

The vaccine market has long been dominated by a public health community determined to provide mass vaccination at very low prices. The market has also been plagued by alarming shortages: the flu vaccine in the 2003-2004 flu season and childhood vaccines several times in recent years. At this conference, four experts will offer their perspectives on how to improve public policies toward vaccine supply, with emphasis on the roles of the industry, the medical community, the Centers for Disease Control, and the Food and Drug Administration.

About the Author

 

John E.
Calfee
  • Economist John E. Calfee (1941-2011) studied the pharmaceutical industry and the Food and Drug Administration (FDA), along with the economics of tobacco, tort liability, and patents. He previously worked at the Federal Trade Commission's Bureau of Economics. He had also taught marketing and consumer behavior at the business schools of the University of Maryland at College Park and Boston University. While Mr. Calfee's writings are mostly on pharmaceutical markets and FDA regulation, his academic articles and opinion pieces covered a variety of topics, from patent law and tort liability to advertising and consumer information. His books include Prices, Markets, and the Pharmaceutical Revolution (AEI Press, 2000) and Biotechnology and the Patent System (AEI Press, 2007). Mr. Calfee wrote regularly for AEI's Health Policy Outlook series. He testified before Congress and federal agencies on various topics, including alcohol advertising; biodefense vaccine research; international drug prices; and FDA oversight of drug safety.

AEI on Facebook